Chemokine blockade as a therapy for renal disease

Chemokines have been verified as inflammatory mediators of experimental nephritis by using anti-chemokine antibodies, chemokine receptor antagonists or targeted chemokine gene disruption. In human disease, chemokines are expressed in the kidney in association with inflammatory infiltrates. Chemokine blockade is thus a potentially novel approach to therapy of inflammatory renal disease. Several anti-chemokine strategies are under development. Effective use of anti-chemokine therapy for renal disease will require a precise understanding of the unique roles that individual chemokines have in renal pathology, and the genetic factors that regulate chemokine expression.